Chapman University announced that it is joining the RAPID Alliance Medications 360 Study, with a goal of transforming how medications and vaccines are delivered in the US from 2022 – 2031.
The RAPID Alliance is a multi-stakeholder research consortium founded in the University of Louisville Center for Health Organization Transformation (CHOT), a National Science Foundation-funded research center.
The all-hands-on-deck effort aims to co-create the RAPID Alliance Medications 360 Framework 2022-2031, a set of transformational strategies and a nationally prioritized research agenda for optimizing the use of medications, vaccinations and other therapies from 2022-2031.
This project is building on a 2020 research study, conducted by UofL researchers during the COVID-19 pandemic, that identified strategic opportunities to improve health and wellbeing for tens of millions of people while reducing spending on likely-avoidable hospitalizations, emergency department and doctor visits by as much as $528 billion dollars.
Chapman University School of Pharmacy (CUSP) will contribute to this effort by supporting research and action with a faculty team that has expertise in state-level strategies for California and beyond, strategic plan integration, community pharmacy transformation, comprehensive medication management services and older adults and chronic care management.
The faculty research team includes professor Dr. Enrique Seoane-Vasquez, PhD; associate professor Dr. Jerika Lam, PharmD; associate professor Dr. Karl Hess, PharmD; assistant professor Dr. Albert Bach, PharmD; assistant professor Dr. Moom Roosan, PharmD, PhD; and assistant professor Yun (Sherry) Wang, PhD.
“We are delighted to be part of this important national effort to co-create new, actionable strategies and research priorities to optimize medication and vaccine use for US populations,” said CUSP Dean Ronald P. Jordan, who is helping lead this project for Chapman University.
“We have a highly qualified six-member team who will design and implement multicenter collaborative efforts that will be carried out by faculty and students at the university. We aim to make a positive change in patient care and reduce the risk of adverse effects from medication while quantifying the value of that in our Southern California communities.”
“We are delighted to see this multi-university research consortium developing,” said Lucinda Maine, Chief Executive Officer of the American Association of Colleges of Pharmacy (AACP) and a founding member of the RAPID Alliance Practice Council. “We believe national and state strategies driven by research are key to optimizing medication use for US populations in the next decade.”
The consortium plans to add up to 30 additional universities in the coming months to support the effort.
Universities participating in the RAPID Alliance and its Medications 360 Study include American University of Health Sciences, Belmont University, Binghamton University, California Northstate University, Chapman University, Ferris State University, Howard University, Lipscomb University, Loma Linda University, Long Island University, Marshall University, Medical College of Wisconsin, Mercer University, North Dakota State University, Oregon Heath & Science University, Oregon State University, South Dakota State University, Sullivan University, Temple University, University of Arkansas for Medical Sciences, University of Cincinnati, University of Colorado, University of Georgia, University of Hawaii Hilo, University of Houston, University of Kentucky, University of Louisville, University of Michigan, University of Mississippi, University of Nebraska Medical Center, University of Nevada Reno, University of Pittsburgh, University of Rhode Island, University of South Carolina, University of Tennessee Health Science Center, Washington State University, Wayne State University, and Western University of Health Sciences.
Learn more, or join the study, at https://meds360.starstudy.link.
